Drugmakers and other experts in the rare disease space urged senators to pressure the FDA to adopt a more flexible approach to the approval process for drugs intended for patients with rare or orphan diseases.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,